YHLO Attends the 7th Cardiac Marker Dialogues Meeting in Glasgow
Recently, the 7th Cardiac Marker Dialogues Meeting (CMD Meeting) was held at the Technology and Innovation Centre, University of Strathclyde, Glasgow, UK. Organized by the UK National External Quality Assessment Service (UK NEQAS) Cardiac Markers program, the meeting was themed "Cardiac Biomarkers: Pathways, POC, and Progress."
It brought together clinical scientists, biomedical scientists, and diagnostics industry representatives from the UK, the US, Norway, Australia, the Netherlands, and other countries to engage in in-depth discussions on core topics including troponin testing standardization, the Fifth Universal Definition of Myocardial Infarction, point-of-care testing pathways, and novel risk prediction biomarkers.
YHLO presented its full portfolio of cardiac biomarker testing solutions at the meeting.

The agenda of this year's CMD Meeting closely addressed clinical pain points and technological innovation.
On the first day, experts provided a systematic interpretation of common issues in troponin testing and the core changes in the Fifth Universal Definition of Myocardial Infarction, facilitating thorough discussion through multiple parallel breakout sessions on the impact of the new definition on clinical practice.
The second day focused on the implementation of accelerated diagnostic pathways and point-of-care testing, with the latest research findings shared on topics including accelerated ACS assessment pathways in emergency departments, clinical applications of POCT high-sensitivity troponin, and pre-hospital testing.
The YHLO team participated in all academic sessions, engaging in in-depth exchanges with global experts on key issues such as troponin testing standardization, consistency and comparability across different testing platforms, and interoperability between POCT and central laboratory results. During the meeting, YHLO showcased at its booth a comprehensive testing menu covering the full spectrum of cardiovascular diseases including myocardial infarction, heart failure, and thrombosis, featuring core assays such as high-sensitivity cardiac troponin I (hs-cTnI) and D-dimer, along with a full-process testing solution based on the chemiluminescence platform.
Multiple attending experts expressed strong interest in YHLO's product performance in the cardiac biomarker field.

Notably, YHLO presented two academic posters at the meeting:
- "A Fully Automated High-Sensitivity Cardiac Troponin I Assay for Whole Blood: Analytical Validation and Clinical Evaluation"
- "Objective Refinement of High-Sensitivity Cardiac Troponin I 99th Percentile Upper Reference Limits in China: Influence of Age and Cholesterol in the Multicenter HARBOR Study."
Both posters drew attention from attending experts, and the "A Fully Automated High-Sensitivity Cardiac Troponin I Assay for Whole Blood: Analytical Validation and Clinical Evaluation" was selected for an oral presentation, further demonstrating YHLO's research depth and international academic influence in cardiac biomarker testing.
In addition, YHLO achieved substantive breakthroughs in collaboration with leading international laboratories, laying a solid foundation for deeper global clinical research cooperation going forward.

Cardiovascular disease is one of YHLO's seven core strategic specialty areas and a key focus of the company's investment and rapid breakthroughs in recent years.
In terms of testing performance, YHLO's hs-cTnI was successfully included in the IFCC's updated High-Sensitivity Cardiac Troponin Reagent Analytical Performance Reference Table (v072025). The IFCC is a global authoritative organization in clinical chemistry and laboratory medicine, and the reference table published by its Committee on Clinical Applications of Cardiac Biomarkers (C-CB) is regarded by the industry as a key benchmark for assessing "high-sensitivity troponin" performance.
This inclusion signifies that YHLO's hs-cTnI has received international authoritative recognition in methodological performance and standardization, providing a more solid reliability guarantee for the clinical application of test results.

In academic research, YHLO is the lead institution for the National "14th Five-Year Plan" Key R&D Program "Diagnostic and Therapeutic Equipment and Biomedical Materials" Special Project — the High-Performance Immunoassay Point-of-Care Rapid Testing System Development Project in China.
This project focuses on the clinical diagnostic and therapeutic needs of acute cardiovascular and cerebrovascular critical care, addressing technical bottlenecks such as high interference and low sensitivity in on-site whole-blood testing. One of the key technologies under development is a cardiovascular and cerebrovascular disease testing system based on microfluidic chemiluminescence technology. It encompasses instruments, reagents, and chips, and is designed to connect the full spectrum of acute chest pain diagnostic needs—from out-of-hospital settings to emergency departments, clinical departments, and central laboratories.
This system has the potential to replace traditional methodologies and address clinical pain points such as large result discrepancies and inconsistent testing standards across different scenarios.
YHLO has also collaborated with leading medical institutions including Fuwai Hospital, Chinese Academy of Medical Sciences, on a series of studies on the clinical diagnostic value of hs-cTnI. Among them, the Chinese Healthy Population High-Sensitivity Cardiac Troponin Reference Interval Study enrolled nearly 3,000 healthy population samples and established the largest and most geographically comprehensive sex-specific reference interval for hs-cTnI in the Chinese healthy population to date. This achievement breaks the long-standing dependence on imported reagents and European/American population data, providing clinicians with diagnostic references more tailored to the characteristics of the Chinese population.

Participation in the CMD Meeting marks an important step in YHLO's internationalization strategy in the cardiac field.
Through this international academic platform, YHLO not only gained valuable opportunities for face-to-face exchanges with leading cardiovascular biomarker experts worldwide but also demonstrated the research strength of a Chinese enterprise in the cardiac biomarker field to the international academic community through two poster presentations and an oral presentation. At the same time, the company gained a clearer understanding of global frontier trends in cardiac biomarker testing, including standardization, POCT adoption, and multi-scenario consistency.
Looking ahead, YHLO will continue to be guided by academic leadership and deepen its R&D and clinical collaboration in cardiac biomarkers. By enriching our testing menu and enhancing product performance, YHLO aims to expand its cardiac diagnostic solutions to more medical scenarios worldwide, benefiting cardiovascular patients globally.
Attachments:
Previous Page
MORE NEWS
China-Hospeq 2026: YHLO Brings Diagnostic Solutions to Global Health Partners
YHLO Brings Diagnostic Solutions to Global Health Partners at China-Hospeq 2026
2026-08-20
ADLM 2026: YHLO Brings Proven Lab Automation to the Americas
YHLO showcases its innovative products and academic achievements at ADLM 2026.
2026-08-01
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China